Details
Following an introductory lecture, workshop participants will divide into breakout sessions based on their experience level as investigators:
- Junior
- Mid-Career/Interim
- Senior
Intended Audience
Researchers at all levels of training/expertise who are interested in clinical trials are welcome to attend.
Presenter
The workshop will be led by Dr. Marcas Bamman, Director of the National Rehabilitation Research Resource to Enhance Clinical Trials (REACT).
Biosketch
- Marcas Bamman, PhD, FACSM:
- Professor, Department of Cell, Developmental, and Integrative Biology
- Director, UAB Center for Exercise Medicine
- Director, P2CHD086851 National Rehabilitation Research Resource to Enhance Clinical Trials (REACT)
- Director, T32HD071866 Interdisciplinary Training in Pathobiology and Rehabilitation Medicine
Exercise profoundly impacts the integrity and function of every major organ system, and is therefore considered the only pluripotent form of medicine available. To maximize impact on disease progression, prevention (i.e. risk factor mitigation), and rehabilitation, the state-of-the-art in research is a focus on dose-response trials to provide the evidence base that yields optimal prescriptions in a disease-specific and population-specific manner. The UAB Center for Exercise Medicine is among the nation’s leaders in this effort, with significant emphasis on exercise as an effective form of regenerative medicine to restore the function of cells, tissues, and whole organ systems that have suffered the consequences of aging, disease, damage, or congenital defects. The Center is currently leading clinical and translational research in aging, Parkinson’s disease, multiple sclerosis, ALS, spinal cord injury, epilepsy, head and neck cancer, heart failure, osteoarthritis, HIV frailty, and post-surgical rehabilitation (i.e. following total joint replacement and organ transplantation).
Over the years Dr. Bamman has directed several exercise clinical trials including randomized dose-response trials focused on aging (e.g., NIH 5R01AG017896, NCT02442479), and he is currently the overall Principal Investigator (PI) or site PI of five, multi-site randomized exercise trials focused on: (i) molecular transducers of exercise-induced health benefits (NIH Common Fund MoTrPAC trial, U01AR071133); total joint arthroplasty rehabilitation (NIH R01HD084124, NCT02628795); (ii) aging with mobility impairment (NIH R01AG046920, NCT02308228); (iii) Parkinson’s disease (Curry Foundation); and (iv) epigenetic determinants of exercise responsiveness (Department of Defense MURI trial). All of his human studies are biologically driven – centered on cellular/ molecular analyses of biospecimens and primary stem cells coupled with thorough in vivo phenotyping in healthy (19 to 83 y/o) and diseased – to better understand mechanisms of exercise-induced improvements in neuromuscular function and muscle mass/quality in the face of atrophy and dysfunction in acute (e.g., surgery, trauma, disuse, burn) or chronic (e.g., Parkinson’s, arthritis, cancer, spinal cord injury) conditions. Dr. Bamman has served on >35 federal review panels and NIH study sections, including a 4-year term serving the NIH/CSR Skeletal Muscle and Exercise Physiology (SMEP) study section.
